DOCSLIB.ORG

5Th European Congress of Immunology Full Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Full Program 5th European Congress of Immunology 2 ECI2018 Table of Content Layout and Graphic Design p. 3 Words of Welcome p. 4 Contact Addresses p. 7 Commitees p. 8 European Congress of Immunology (ECI) p. 9 European Federaion of Immunological Socieies (EFIS) p. 10 Acteria Prizes awarded by EFIS & EFIS/EJI Ita Askonas Award p. 12 More EFIS Awards p. 13 Travel Grants p. 14 Hours of Operaion p. 18 Informaion for Speakers and Poster Presenters p. 22 CME Accreditaion p. 23 Conference Venue: Overview p. 24 Conference Venue: Room Plans p. 25 Program Overview p. 26 Scieniic Program p. 30 Business Meeings p. 33 Scieniic Satellite Meeings p. 34 Joint Symposia p. 35 Hands-on Workshops p. 38 Educaional Sessions p. 40 Men and Women in Immunology p. 41 Keynote Lectures p. 42 Scieniic Program By Day p. 46 Industry Sponsored Symposia, Sponsoring and Exhibiion p. 89 Acknowledgements p. 90 Company Descripions p. 92 Industry Sponsored Symposia p. 94 Exhibiion Informaion p. 95 Exhibiion Floor Plan p. 96 Exhibitors (A-Z) p. 97 Networking Events p. 101 The City of Amsterdam p. 102 5th European Congress of Immunology, September 2-5, 2018, Amsterdam, NL 3 ECI2018 Editors ECI2018 Congress President Prof. Dr. Marieke van Ham Head Dept. of Immunopathology Sanquin Research and SILS, Faculty of Science, University of Amsterdam Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands [email protected] ECI2018 Scientific Program Committee President Prof Dr. Jaques Neejes Leiden University Medical CenterDepartment of Cell & Chemical Biology P.O. Box 9600 , 2300 RC Leiden, The Netherlands [email protected] ECI2018 Local Organizing Committee President Janneke N. Samsom, PhD Erasmus University Medical Center Laboratory of Pediatric Gastroenterology P.O. Box 2040, 3000 CA Roterdam, The Netherlands [email protected] ECI2018 and EFIS President’s Office Chrisina Helbig, PhD Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands [email protected] Layout and Graphic Design ECI2018 and EFIS President’s Office Chrisina Helbig, PhD Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands [email protected] ECI2018 Logo designed by Barbara Biegl, www.biegl-graik.at 5th European Congress of Immunology, September 2-5, 2018, Amsterdam, NL 4 ECI2018 Words of Welcome Welcome by the Congress President Dear Colleagues and Friends, With great pleasure we welcome you on behalf of the Dutch Society for Immunology (NVVI) and the European Federaion of Immunological Socieies (EFIS) to the 5th European Congress of Immunology (ECI) in Amsterdam from September 2-5, 2018. The 5th ECI covers all ields of modern immunology. The special focus of the 5th ECI is ‘Building Bridges’. The Dutch take pride in being expert bridge builders, physically to live among opulent environmental water, but also iguraively to connect people and facilitate mutual goals. The layout of ECI2018 has been speciically made with the ‘Building Bridges’-concept in mind: • For the Program of this 5th ECI, people from immunological socieies all over Europe and the rest of the world have intensely collaborated. We atempt to build an European village of immunology in Amsterdam. Our program ofers 150+ state-of-the ield talks by invited top of the bill immunologists and front-runners in clinical immunomodulatory therapies. Novel Educaional Sessions will bring you up to date for speciic topics. Pre- and postmeeing Scieniic Satellite Meeings give added in-depth insights into speciic ields of immunology. • Our new set-up of the ECI meeing tracks connects immunological research to clinical applicaions in speciic medical ields to bring biomedical and medical researchers together. • The Poster Sessions form the heart of the meeing. Therefore, they have been given extra ime in the program. Guided Poster Walks will allow strong exposure of all research and simulate discussions and networking. From each poster session, a candidate will be selected to move her/his poster to the Best Posters Area to contest for the poster awards. • Up-and-coming scienists, who are changing current immunological concepts through novel scieniic approaches, will be given ample room to the stage. More than 370 oral presentaions have be selected from submited abstracts for the Workshops. The best rated abstracts of young scienists have been selected for Bright Sparks Sessions. • With help of editors of high impact peer-reviewing journals, Late Breaking Hot Topics have been ideniied. These data will be presented before the Keynote lectures. • We have brought in scienists from interdisciplinary ields, like systems biology and bioinformaics. A direct interacion with them is achieved in our hands-on workshops “Deep thinking in Immunology”. Paricipants will acively model or analyze data on their own PC. They will learn how systems biology and funcional genomics integrate data into ‘deep’ (large), analyical and mathemaical models to enhance mechanisic understanding and help test hypotheses. We have much enjoyed the truly internaional efort to make an atracive program for ECI2018 and thank you for that. We much value all of your eforts to join our meeing and to take part in the internaional exchange of scieniic thoughts and ideas. While you are here, you may have a chance to discover the other faces of the Netherlands, like Amsterdam with its many canals (165), bridges (1281), enchaning canal houses, small streets and vivid markets. Over the centuries, Amsterdam has been a place of refuge for people from many diferent backgrounds. Nowadays, Amsterdam is home to people of 180 naionaliies, making it a true meling pot of naions with cosmopolitan lair. We enjoy that we can host you here and hope that you will enjoy ECI2018 in return! With best wishes, Marieke van Ham, ECI2018 Congress President 5th European Congress of Immunology, September 2-5, 2018, Amsterdam, NL 5 ECI2018 Welcome by the NVVI President Dear Colleagues and Friends, The Dutch Society for Immunology (NVVI) welcomes you to the 5th European Congress of Immunology, ECI2018. We are very glad to organize ECI2018 on behalf of the European Federaion of Immunological Socieies (EFIS). The Netherlands has a large immunological society, with strong historic roots. Already during the Dutch Golden Age (17th century), biomedical science was popular. Anatomy lessons, as painted by Rembrandt, were social instrucive events. Antonie van Leeuwenhoek created highly magnifying microscopes that boosted the scieniic understanding of the world of microbes and eukaryoic cells. Over the years, immunology lourished. Geert Reinders (1737-1815) was the irst to use vaccinaion against “Rinderpest”. One of the irst great European immunopathologists, Joghem van Loghem, was born in Amsterdam in 1914. The irst blood bank in coninental Europe was organized 1940 in The Hague. At Leiden University Jon van Rood pioneered in the discovery of the HLA system and put his indings into clinical pracice in solid organ and bone marrow transplantaion. To date immunological research and its clinical applicaions is sill thriving in the Netherlands. The mission of the NVVI is to acively promote and support: • Excellence in immunological research, immunodiagnosic procedures and clinical immunological pracice in the Netherlands • High quality of analyses of immunological parameters used in health care (for diagnosic purposes) • The societal posiion of the professional immunologist in all disciplines. To achieve this, the NVVI organizes scieniic and educaional meeings in the ield of immunology, maintains internaional contacts and has established a number of commitees that regulate scieniic, laboratory and clinical standards in immunology. In addiion, the NVVI strives to provide input to naional and internaional policies with the objecive to strengthen the future of immunology in all disciplines. In line with our mission, we consider it a privilege to organise ECI2018 for the internaional immunological society. We hope to share with you our vision on immunology, ranging from immunological biomedical research to clinical applicaions of immunomodulatory therapies and basic and specialised educaion in the ield of immunology. We look very much forward to the exchange of the latest indings in the ield of immunology through inspiring presentaions and open scieniic discussions at ECI2018. With our best wishes, Reina Mebius, President NVVI 5th European Congress of Immunology, September 2-5, 2018, Amsterdam, NL 6 ECI2018 Welcome from the EFIS President Dear Friends and Colleagues, As President of the European Federaion of Immunological Socieies (EFIS), it is my pleasure to welcome you in Amsterdam at the 5th European Congress of Immunology (ECI2018). Held every three years and regularly atracing over 3000 delegates, the ECI is now regarded as a premier venue on the internaional immunology calendar. The most recent ECI2015 in Vienna was a telling example of the success that the congress now enjoys. And ECI2018 in Amsterdam promises to coninue this tradiion by staging a truly memorable scieniic event for all atending. EFIS, together with our local host, the Dutch Society for Immunology, will work to ensure a simulaing three and one-half days during which paricipants – young and not so young, alike – will have the opportunity to interacively explore the most recent advances in the ields of innate immunity, adapive immunity, diseases of the immune system and immune intervenions. And whether you have a broad-ranging interest in the muliple facets of modern immunological research, or your focus lies in a paricular niche, you will surely come away from ECI2018 saisied
Recommended publications
  • REPORTER No 6396 W E D N E S D Ay 23 S E P T E M B E R 2015 V O L C X Lv I N O 1

    REPORTER No 6396 W E D N E S D Ay 23 S E P T E M B E R 2015 V O L C X Lv I N O 1

    CAMBRIDGE UNIVERSITY REPORTER NO 6396 W ED N E S D AY 23 S EPTEMBER 2015 V OL CXLV I N O 1 CONTENTS Notices Notices by Faculty Boards, etc. Calendar 2 Natural Sciences Tripos, Part II (Biological Notice of a Discussion on Tuesday, 13 October and Biomedical Sciences), 2015–16 11 2015 2 Natural Sciences Tripos, Part III (Experimental Preacher at Mere’s Commemoration in 2016 2 and Theoretical Physics) and Master of Nomination of the Proctors and Deputy Advanced Studies in Physics, 2015–16 12 Proctors for 2015–16 2 Form and conduct of examinations, 2016 Annual Reports 2 Asian and Middle Eastern Studies Tripos, Examination results statistics 2 Part II, 2016: correction 13 Vacancies, appointments, etc. Obituaries Electors to the Professorship of Comparative Obituary Notices 14 Philology 3 Graces Electors to the Professorship of Immunology 3 Grace submitted to the Regent House on Electors to the Sir Patrick Sheehy 23 September 2015 14 Professorship of International Relations 3 Acta Electors to the Professorship of Medieval History 4 Approval of Grace submitted to the Regent Electors to the William Wyse Professorship of House on 29 July 2015 14 Social Anthropology 4 Vacancies in the University 4 End of the Official Part of the ‘Reporter’ Elections, appointments, reappointment, and College Notices grants of title 5 Elections 15 Awards, etc. Vacancies 16 Scholarships and Prizes, etc. awarded 7 Other Notices 17 Events, courses, etc. Notice by the University Bellringer 17 Announcement of lectures, seminars, etc. 8 External Notices Notices by the General Board University of Oxford 17 Regulations for the University Library 9 The Cambridge Humanities Research Grants Scheme 9 Regulations for examinations Classical Tripos, Part II 10 Modern and Medieval Languages Tripos, Part IB 10 Bachelor of Theology for Ministry 10 PLISUB HED BY AUTHORITY 2 CAMBRIDGE UNIVERSITY REPORTER 23 September 2015 NOTICES Calendar 1 October, Thursday.
  • Dem Dort Tätigen Herrn E. Van Der Meulen Gelassen Habe

    Dem Dort Tätigen Herrn E. Van Der Meulen Gelassen Habe

    Übersetzung aus der niederländischen Sprache Heute, am sechzehnten Juni zweitausendzwanzig, habe ich, Franciscus Stephanus Kroesemeijer, Gerichtsvollzieher-Anwärter, tätig in der Geschäftsstelle von Diana Johanna Vermeulen, Gerichtsvollzieher mit Niederlassungsort Delft, Niederlande, und mit Geschäftsstelle an der Wallerstraat 14c-16c auf Ersuchen von 1. WILLEM ENGEL, wohnhaft in Rotterdam, 2. der Stiftung VIRUSWAARHEID.NL, mit Sitz in Rotterdam, 3. JEROEN SEBASTIAAN POLS, wohnhaft in Vogelenzang, Gemeinde Bloemendaal; die alle für diese Sache folgenden Wohnort wählen: Nieuwe Prinsenkade 10 in (4811 VC) Breda, die die Anschrift der Anwaltskanzlei Lexion Advocaten, von welcher Kanzlei Anwalt mr. G.C.L. van de Corput, für diese Sache zum Anwalt bestellt wird, AUF GRUND DES DAZU ERTEILTEN BEFEHLS DES ANORDNUNGSRICHTERS FOLGENDE PERSON IM EILVERFAHREN GELADEN DIE JURISTISCHE PERSON ÖFFENTLICHEN RECHTS „STAAT DER NEDERLANDEN“ [Staat der Niederlande] insbesondere das [niederländische Ministerium für Gesundheit, Wohlergehen und Sport] „Ministerie van Volksgezondheid, Welzijn en Sport“, Direktorat Rechtssystem Abteilung Rechtsprechung & Konfliktlösung mit Sitz in Den Haag, wobei ich auf Grund von Artikel 48 Rv. [des niederländisch Zivilprozessrechts] meine Ladungsurkunde im Amtsraum des Generalanwalts beim „Hoge Raad der Nederlanden“ [obersten Gerichtshof der Niederlande] mit Sitz in (2514 CV) Den Haag, Kazernestraat Nr. 52, zugestellt habe und und eine Abschrift hiervon bei dem dort tätigen Herrn E. van der Meulen gelassen habe, (die hier im Weiteren zu nennenden Beweisstücke werden später in das Verfahren eingebracht) UM: am, Donnerstag, dem 25. Juni zweitausendzwanzig, morgens um 11:00 Uhr, persönlich oder durch einen Anwalt vertreten zur Sitzung in einem Eilverfahren vor dem Anordnungsrichter beim Gericht Den Haag, Standort Den Haag, mit der Anschrift Prins Clauslaan 60 zu erscheinen; ANKÜNDIGUNGEN Dabei habe ich der Geladenen Folgendes mitgeteilt: a.
  • Immune Homeostasis

    Immune Homeostasis

    IMMUNE HOMEOSTASIS FUNDED PROJECTS FROM THE INNOVATION WORKSHOP 18-20 JULY 2017 AIMS THE SANDPIT PROCESS CAN BE BROKEN DOWN The immune system continues to intrigue and test us: as we get closer to finding ways of harnessing or modulating immune responses, new and unexpected consequences and INTO SEVERAL STAGES: challenges present themselves, often testing even our most fundamental understanding. Cancer Research UK and Arthritis Research UK came together to engage the research community to tackle the specific challenge of understanding how the immune system regulates itself under normal physiological conditions (immune homeostasis), how it is • Defining the scope of the challenge dysregulated in different diseases and how we can stimulate the immune response to prevent • Sharing understanding of the challenge and expertise brought to the sandpit by or treat disease (immunotherapy). participants We brought together researchers and clinicians in the fields of inflammatory disease, cancer, • Evolving common languages and terminologies amongst people from a diverse theoretical physics, computational medicine and other areas, whose expertise could be applied range of backgrounds and disciplines to the key questions concerning immune homeostasis. This workshop encouraged participants from a diverse range of backgrounds to melt barriers, develop a common language to promote • Breaking down preconceptions of researchers and stakeholders collaboration, and suggest new ways to harness the immune system to treat disease. • Taking part in break-out sessions focussed on challenges, using creative thinking techniques Director • Capturing outputs in the form of highly innovative feasibility study proposals The role of the Director was to work with the facilitators to lead the event and guide the process • A funding decision on those proposals at the sandpit, using “real time” peer-review.
  • 39Th International Symposium on High-Performance Liquid Phase

    39Th International Symposium on High-Performance Liquid Phase

    HPLC 2013 39th International Symposium on High Performance Liquid Phase Separations and Related Techniques RAI CONGRESS CENTRE THE NETHERLANDS 16-20 JUNE 2013 Final Program Contents Welcome Message ...................................................................................................................................................... 3 Sponsors ...................................................................................................................................................................... 4 Media Partners ........................................................................................................................................................... 7 Supporting Organizations ........................................................................................................................................... 8 Committees ................................................................................................................................................................. 9 History and Future Meetings .................................................................................................................................... 10 Awards ...................................................................................................................................................................... 12 Short Courses ............................................................................................................................................................ 14 Lecture
  • Heros Deliverable Tem^Late

    Heros Deliverable Tem^Late

    VU Research Portal D1.1 – Recommendations for governance and policies in the n-COV-2019 response Boersma, FK; Kyratsis, Ioannis; de Vries, Marion; Clark, Nathan Edward; Rollo, Agnese; Falagara Sigala, Ioanna ; Alani, Harith; Larruina, Robert; Berg, Rinske 2020 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Boersma, FK., Kyratsis, I., de Vries, M., Clark, N. E., Rollo, A., Falagara Sigala, I., Alani, H., Larruina, R., & Berg, R. (2020). D1.1 – Recommendations for governance and policies in the n-COV-2019 response. EU. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 02. Oct. 2021 D1.1 – Recommendations for governance and policies in the n-COV-2019 response
  • Consolidated Annual Activity Report 2020

    Consolidated Annual Activity Report 2020

    ECDC CORPORATE Consolidated Annual Activity Report 2020 www.ecdc.europa.eu ECDC CORPORATE Consolidated Annual Activity Report 2020 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by the Executive Office. Suggested citation: European Centre for Disease Prevention and Control. Consolidated Annual Activity Report. Stockholm: ECDC; 2021. Stockholm, June 2021 PDF ISBN 978-92-9498-539-2 doi: 10.2900/186919 Catalogue number TQ-02-21-732-EN-N © European Centre for Disease Prevention and Control, 2021 Reproduction is authorised, provided the source is acknowledged ii CORPORATE REPORT Consolidated Annual Activity Report Contents Consolidated annual activity report 2020 ........................................................................................................... i Abbreviations ................................................................................................................................................ v Management Board analysis and assessment .................................................................................................... 1 Foreword by the Chair of the Management Board ............................................................................................. 2 Introduction by the Director ............................................................................................................................ 3 Executive summary .......................................................................................................................................
  • Pnas11052ackreviewers 5098..5136

    Pnas11052ackreviewers 5098..5136

    Acknowledgment of Reviewers, 2013 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2013. Their generous contribution is deeply appreciated. A Harald Ade Takaaki Akaike Heather Allen Ariel Amir Scott Aaronson Karen Adelman Katerina Akassoglou Icarus Allen Ido Amit Stuart Aaronson Zach Adelman Arne Akbar John Allen Angelika Amon Adam Abate Pia Adelroth Erol Akcay Karen Allen Hubert Amrein Abul Abbas David Adelson Mark Akeson Lisa Allen Serge Amselem Tarek Abbas Alan Aderem Anna Akhmanova Nicola Allen Derk Amsen Jonathan Abbatt Neil Adger Shizuo Akira Paul Allen Esther Amstad Shahal Abbo Noam Adir Ramesh Akkina Philip Allen I. Jonathan Amster Patrick Abbot Jess Adkins Klaus Aktories Toby Allen Ronald Amundson Albert Abbott Elizabeth Adkins-Regan Muhammad Alam James Allison Katrin Amunts Geoff Abbott Roee Admon Eric Alani Mead Allison Myron Amusia Larry Abbott Walter Adriani Pietro Alano Isabel Allona Gynheung An Nicholas Abbott Ruedi Aebersold Cedric Alaux Robin Allshire Zhiqiang An Rasha Abdel Rahman Ueli Aebi Maher Alayyoubi Abigail Allwood Ranjit Anand Zalfa Abdel-Malek Martin Aeschlimann Richard Alba Julian Allwood Beau Ances Minori Abe Ruslan Afasizhev Salim Al-Babili Eric Alm David Andelman Kathryn Abel Markus Affolter Salvatore Albani Benjamin Alman John Anderies Asa Abeliovich Dritan Agalliu Silas Alben Steven Almo Gregor Anderluh John Aber David Agard Mark Alber Douglas Almond Bogi Andersen Geoff Abers Aneel Aggarwal Reka Albert Genevieve Almouzni George Andersen Rohan Abeyaratne Anurag Agrawal R. Craig Albertson Noga Alon Gregers Andersen Susan Abmayr Arun Agrawal Roy Alcalay Uri Alon Ken Andersen Ehab Abouheif Paul Agris Antonio Alcami Claudio Alonso Olaf Andersen Soman Abraham H.
  • 2018 IID Meeting, Orlando, Florida

    2018 IID Meeting, Orlando, Florida

    May 16-19, 2018 MEETING PROGRAM Rosen Shingle Creek Resort Orlando, Florida www.IID2018.org IID 2018 MEETING IID 2018 Program Chairs and Final Reviewers ESDR - Program Chairs JSID - Program Chairs SID - Program Chairs Michel Gilliet, MD Manabu Fujimoto, MD Nicole Ward, PhD Matthias Schmuth, MD Manabu Ohyama, MD/PhD Victoria Werth, MD ESDR – Final Reviewers JSID – Final Reviewers SID – Final Reviewers Hervé Bachelez, MD/PhD Riichiro Abe, MD/PhD Vladimir Botchkarev, MD/PhD Leopold Eckhart, PhD Manabu Fujimoto, MD Spiro Getsios, PhD Menno de Rie, MD/PhD Minoru Hasegawa, MD Daniel Kaplan, MD/PhD Bernhard Homey, MD Hironobu Ihn, MD/PhD Ethan Lerner, MD/PhD David Kelsell, PhD Kenji Kabashima, MD/PhD Lloyd Miller, MD/PhD Lionel Larue, PhD Takuro Kanekura, MD/PhD Peggy Myung, MD/PhD Caterina Missero, PhD Norito Katoh, PhD Marjana Tomic-Canic, PhD Edel O’Toole, PhD Tatsuyoshi Kawamura, MD/PhD Kevin Wang, MD/PhD Ralf Paus, MD/PhD Akiharu Kubo, MD/PhD Nicole Ward, PhD Sirkku Peltonen, MD/PhD Akimichi Morita, MD/PhD Victoria Werth, MD Neil Rajan, MD/PhD Manabu Ohyama, MD/PhD Martin Steinhoff, MD/PhD Ryuhei Okuyama, MD/PhD Marta Szell, DSc Tamio Suzuki, MD/PhD Thomas Werfel, MD Katsuto Tamai, MD/PhD Peter Wolf, MD Akemi Yamamoto, MD/PhD European Society for Japanese Society for Society for Investigative Dermatological Research Investigative Dermatology Dermatology Rue Cingria 7, Geneva 5F, 4-1-4 Hongo, Bunkyo-ku, Tokyo 526 Superior Avenue East, Suite 340 Switzerland, 1205 113-0033, Japan Cleveland, Ohio 44114, USA Tel: +41 22 321 48 90 Tel: +81-3-3830-0068 Tel: +01 216-579-9300 Email: [email protected] Email: [email protected] Email: [email protected] Web: www.esdr.org Web: www.jsid.org Web: www.sidnet.org ACKNOWLEDGEMENTS The organizers of IID 2018 gratefully acknowledge the many exhibitors and sponsors whose attendance has helped make this meeting possible.
  • The Following Is a Draft Translation of the Summons by Jeroen Pols and Willem De Engel Seeking an Immediate End to the Lockdown Measures

    The Following Is a Draft Translation of the Summons by Jeroen Pols and Willem De Engel Seeking an Immediate End to the Lockdown Measures

    (The following is a draft translation of the summons by Jeroen Pols and Willem de Engel seeking an immediate end to the lockdown measures. Pol and de Engel are part of the group Viruswaanzin) Introduction 1. On 27 February 2020, the first contamination of COVID-19 was detected in the Netherlands. After the WHO classified the outbreak as a pandemic on 11 March 2020, all countries worldwide proceeded to take drastic measures on an unprecedented scale in modern history. In the Netherlands, the outbreak led to strict measures whereby social traffic was virtually shut down due to the closure of schools, universities, libraries, museums, cinemas, restaurants, cafes, gyms, and barbershops. In addition, heavy restrictions have been placed on the freedom of movement of the population, which means that even the non-closed part of society is limited to a very small number of people and can only function to a limited extent. The use of emergency ordinances has been used to enforce these social restrictions and everyone has been urged to stay at home as much as possible. Recreational areas and sports facilities have also been closed or made inaccessible.After more than two months of measures, the official death toll in the Netherlands is 5,830 (persons who died with COVID-19, up until 25 May 2020). Although the actual number that have died with COVID-19 is significantly higher, it has now been established that the virus has only contributed substantially to the cause of death in a few cases. The elderly with underlying health conditions were particularly susceptible to the virus.
  • Naar Aanleiding Van De Update Van De Webpagina 'Aanvullende Informatie Diagnostiek COVID-19 Bijlage Bij De LCI-Richtlijn COVID

    Naar Aanleiding Van De Update Van De Webpagina 'Aanvullende Informatie Diagnostiek COVID-19 Bijlage Bij De LCI-Richtlijn COVID

    Toelichting op vraag van Haga aan Jaap van Dissel RIVM A. van Leeuwenhoeklaan 9 Naar aanleiding van de update van de webpagina ‘Aanvullende informatie 3721 MA Bilthoven Postbus 1 diagnostiek COVID-19 Bijlage bij de LCI-richtlijn COVID-19 | Versie 25 september 3720 BA Bilthoven 2020’ (https://lci.rivm.nl/covid-19/bijlage/aanvullend) zijn een aantal vragen www.rivm.nl gesteld. Updates van deze bijlage naar de huidige stand van ontwikkelingen en T 030 274 91 11 inzichten vinden regelmatig plaats. [email protected] Vraag: waarom is de afkapwaarde voor de Ct-waarde bij de PCR aangepast? RIVM 15 oktober 2020 Deze vraag refereert naar de volgende zinsnede in het document: Daar stond in de voorgaande versie van het document de Ct-waarde >30. De onderliggende vraag bij de vraag naar aanpassing van deze waarde suggereert dat het hier gaat om een afkapwaarde die onderscheid maakt tussen positief en negatief. Dat is niet zo. Het gaat hier om een waarschuwingswaarde. Ct-waarden van COVID-19 patiënten kunnen typisch variëren van circa 15 tot 40, met de meerderheid tussen 20 en 35 (grenzen afhankelijk van gebruikte apparatuur en chemie voor de PCR-test). Tegen de limiet van detectie van de PCR-test die zich typisch tussen Ct 35 en 40 bevindt, moeten de amplificatiecurves extra goed bekeken worden of ze aan de S-curve eis voldoen. De tekst gaat over de Ct-waarde waarboven men extra alert moet zijn bij beoordelen van de amplificatiecurves. Het betreft een aanwijzing die kan helpen bij de beoordeling van de diagnostiek. Sommige laboratoria gebruiken om te bepalen of de PCR-test positief of negatief is een Ct afkapwaarde of andere afkapwaarde voor methoden waarbij geen Ct-waarde wordt gegenereerd.
  • 2020 Zlatareva Iva 1521303 E

    2020 Zlatareva Iva 1521303 E

    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Tissue-specific butyrophilin-like proteins are TCR selecting ligands distinct from antigens Zlatareva, Iva Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 10. Oct. 2021 Tissue-specific butyrophilin-like proteins are gdTCR selecting ligands distinct from antigens Iva Ivanova Zlatareva King’s College London PhD Supervisors: Professor Adrian C.
  • Estimation of COVID-19 Prevalence from Serology Tests: a Partial Identification Approach Panos Toulis JUNE 2020

    Estimation of COVID-19 Prevalence from Serology Tests: a Partial Identification Approach Panos Toulis JUNE 2020

    WORKING PAPER · NO. 2020-54 Estimation of COVID-19 Prevalence from Serology Tests: A Partial Identification Approach Panos Toulis JUNE 2020 5757 S. University Ave. Chicago, IL 60637 Main: 773.702.5599 bfi.uchicago.edu Estimation of Covid-19 Prevalence from Serology Tests: A Partial Identification Approach Panos Toulis∗ University of Chicago, Booth School of Business Abstract We propose a partial identification method for estimating disease prevalence from serology studies. Our data are results from antibody tests in some population sample, where the test parameters, such as the true/false positive rates, are unknown. Our method scans the entire parameter space, and rejects parameter values using the joint data density as the test statistic. The proposed method is conservative for marginal inference, in general, but its key advantage over more standard approaches is that it is valid in finite samples even when the underlying model is not point identified. Moreover, our method requires only independence of serology test results, and does not rely on asymptotic arguments, normality assumptions, or other approximations. We use recent Covid-19 serology studies in the US, and show that the parameter confidence set is generally wide, and cannot support definite conclusions. Specifically, recent serology studies from California suggest a prevalence anywhere in the range 0%-2% (at the time of study), and are therefore inconclusive. However, this range could be narrowed down to 0.7%-1.5% if the actual false positive rate of the antibody test was indeed near its empirical estimate (∼0.5%). In another study from New York state, Covid-19 prevalence is confidently estimated in the range 13%-17% in mid-April of 2020, which also suggests significant geographic variation in Covid-19 exposure across the US.